FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has applied for conditional approval of its prostate-cancer radiopharmaceutical and gained approval for a Korean Phase 3.

  • Announced approval of a 150-patient Korean Phase 3 plan for 177Lu-DGUL. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Medical & MSL

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Cellbion

A developer of radiopharmaceuticals for cancer, whose lead prostate-cancer candidate is 177Lu-DGUL (poqubotide satetracetin).

177Lu-DGUL

Phase 3

A PSMA-targeted radiopharmaceutical for metastatic castration-resistant prostate cancer; a 150-patient Korean Phase 3 was approved in September 2026 and conditional marketing approval has been applied for.

177Lu-DGUL + Keytruda

Stage unconfirmed

Combination with MSD's checkpoint inhibitor Keytruda under a clinical collaboration and supply agreement signed in February 2025.

Completion reported

Received MFDS approval of the Korean Phase 3 trial plan for 177Lu-DGUL.

Completion reported

Applied to the MFDS for conditional marketing approval of 177Lu-DGUL.

Official role guide

Cellbion careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 셀비온, MSD 키트루다와 'Lu-177-DGUL' 병용 임상 협력 계약 체결 ↗머니투데이 · Published 2025-02-05 · Sources checked 2026-11-18 · Original unavailable
  2. 셀비온, 전립선암 방사성의약품 후보물질 임상 3상 승인 ↗한국경제 · Published 2026-09-29 · Sources checked 2026-11-18 · Original unavailable